Seres Therapeutics (FRA:1S9) 3-Year EBITDA Growth Rate : 9.60% (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Seres Therapeutics 3-Year EBITDA Growth Rate?

Seres Therapeutics's EBITDA per Share for the three months ended in Sep. 2024 was €-0.29.

During the past 3 years, the average EBITDA Per Share Growth Rate was 9.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 10.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -5.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Seres Therapeutics was 34.80% per year. The lowest was -151.30% per year. And the median was 1.00% per year.

Competitive Comparison of Seres Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Seres Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seres Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seres Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Seres Therapeutics's 3-Year EBITDA Growth Rate falls into.

Seres Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Seres Therapeutics (FRA:1S9) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Seres Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Seres Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Seres Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seres Therapeutics Inc (FRA:1S9) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

MCRB:USA

Address

101 Cambridgepark Drive, Cambridge, MA, USA, 02140

Website

https://www.serestherapeutics.com

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Seres Therapeutics Headlines

No Headlines